Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma - PubMed (original) (raw)

Comparative Study

. 2005 Oct;447(4):695-700.

doi: 10.1007/s00428-005-0003-6. Epub 2005 Oct 19.

Affiliations

• PMID: 16075292
• DOI: 10.1007/s00428-005-0003-6

Comparative Study

Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma

Cristina Riva et al. Virchows Arch. 2005 Oct.

Abstract

Androgens and androgen receptors (AR) are involved in the pathogenesis of breast cancer. Epidemiological studies have shown a significant association between the risk of breast cancer and androgens. However, the functional role and clinical value of AR expression in breast carcinoma have still not been clearly defined. The present study was set up to investigate the prevalence of ARs in a series of consecutive invasive breast carcinomas (IBCs) and to evaluate the patterns of AR phenotypes in a series of selected invasive lobular carcinomas (ILCs). Among the 250 consecutive IBCs (consisting of 212 ductal and 38 lobular neoplasms), AR immunoreactivity was observed in 151/250 (60.4%) cases, being expressed in 118/212 (56%) ductal and 33/38 (87%) lobular carcinomas (a statistically significant difference, chi2=11.82). AR expression was frequently associated with ER (65.2%, chi2=14.33) and PR positivity (66.9%, chi2=7.36). Most AR positive cases showed a low proliferative index (63.7%) and a low or intermediate histological grade (G1-G2, 63.9%). Among the 80 selected ILCs, AR expression was observed in 64/80 (80%) cases. Our results confirm that ARs are expressed in most breast cancers. Moreover, we demonstrated that AR positivity is particularly marked in lobular neoplasms. In addition, AR positive carcinomas are frequently characterized by a low or intermediate grade, a low proliferative index and ER and/or PR co-expression.

PubMed Disclaimer

Similar articles

• Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer.
  Narita D, Raica M, Suciu C, Cîmpean A, Anghel A. Narita D, et al. Folia Histochem Cytobiol. 2006;44(3):165-72. Folia Histochem Cytobiol. 2006. PMID: 16977795
• Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
  Sasano H, Kimura M, Shizawa S, Kimura N, Nagura H. Sasano H, et al. J Clin Endocrinol Metab. 1996 Aug;81(8):3063-7. doi: 10.1210/jcem.81.8.8768875. J Clin Endocrinol Metab. 1996. PMID: 8768875
• Estrogen receptor content in malignant breast tumors in men--a review.
  Olsson H. Olsson H. J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):283-7. doi: 10.1023/a:1009546811429. J Mammary Gland Biol Neoplasia. 2000. PMID: 14973390 Review.
• Androgen Receptor (AR) Expression in Invasive Male Breast Carcinoma (MBC): An International Multi-Institutional Review of 168 Cases Emphasizing the Potential Use of AR as a Therapeutic Target.
  Stolnicu S, Moncea D, Dema A, Geambasu S, Moldovan C, Comanescu M, Voidazan S, Georgescu R, Alvarado-Cabrero I, Resetkova E, Buiga R. Stolnicu S, et al. Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):e18-e20. doi: 10.1097/PAI.0000000000000376. Appl Immunohistochem Mol Morphol. 2017. PMID: 28177976 Review. No abstract available.

Cited by

• Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research.
  Witt BL, Tollefsbol TO. Witt BL, et al. Life (Basel). 2023 Dec 8;13(12):2311. doi: 10.3390/life13122311. Life (Basel). 2023. PMID: 38137912 Free PMC article. Review.
• Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years.
  Alsughayer AM, Dabbagh TZ, Abdel-Razeq RH, Al-Jussani GN, Alhassoon S, Sughayer MA. Alsughayer AM, et al. JCO Glob Oncol. 2022 Mar;8:e2100359. doi: 10.1200/GO.21.00359. JCO Glob Oncol. 2022. PMID: 35436143 Free PMC article.
• Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.
  Sivadas A, Kok VC, Ng KL. Sivadas A, et al. Breast Cancer Res Treat. 2022 Jun;193(2):361-379. doi: 10.1007/s10549-022-06567-7. Epub 2022 Mar 29. Breast Cancer Res Treat. 2022. PMID: 35348974
• Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
  Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Mouabbi JA, et al. Breast Cancer Res Treat. 2022 Jun;193(2):253-264. doi: 10.1007/s10549-022-06572-w. Epub 2022 Mar 26. Breast Cancer Res Treat. 2022. PMID: 35347549 Review.
• AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
  De Amicis F, Chiodo C, Morelli C, Casaburi I, Marsico S, Bruno R, Sisci D, Andò S, Lanzino M. De Amicis F, et al. BMC Cancer. 2019 Nov 4;19(1):1038. doi: 10.1186/s12885-019-6262-4. BMC Cancer. 2019. PMID: 31684907 Free PMC article.

References

1. 1. Br J Surg. 1980 Mar;67(3):153-69 - PubMed
2. 1. Cancer Res. 1980 Jul;40(7):2557-61 - PubMed
3. 1. J Histochem Cytochem. 1993 May;41(5):671-8 - PubMed
4. 1. Breast Cancer Res. 2003;5(3):164-73 - PubMed
5. 1. J Natl Cancer Inst. 1996 Mar 6;88(5):291-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program